NantKwest/ImmunityBio's COVID-19 Vaccine Candidate To Be Tested For Oral And Sublingual Route Of Administration

by Vandana Singh, Benzinga Editor
February 12, 2021 5:25 AM | 2 min read |
  • The FDA has signed off the expansion of Phase 1 testing of a COVID-19 vaccine candidate, developed by NantKwest Inc's NK merger partner, ImmunityBio Inc, to include sublingual boosts (cohort C expansion) to the currently active multi-cohort trial of the subcutaneous version of the vaccine.
  • The agency also authorized a second Phase 1 study that will examine the addition of an oral boost to the subcutaneous prime administration. As a result, the companies will enroll another 105 participants in the U.S. trials.
  • The combination of an oral boost with a subcutaneous prime is based on the findings reported in the NIH/BARDA-sponsored Non-Human Primate study, which showed that when administered with an oral boost, the bivalent vaccine resulted in potent stimulation of spike (S) and nucleocapsid (N)-specific T cells with potent antibody release from memory B cells following viral challenge.
  • Additionally, activation of the full immune system by S and N proteins resulted in complete viral clearance of SARS-CoV-2 in lung and nasal passages following the challenge.
  • Both oral and sublingual trials are anticipated to begin this month. The optimal combination of the route of administration and dose will be determined.
  • The company says that room-temperature stable formulations for oral delivery can potentially solve the cold-chain challenges of distribution and the ability to generate mucosal IgA antibody barriers to the virus in the upper respiratory tract where it first enters the body.
  • In December last year, ImmunityBio announced an all-stock transaction with NantKwest, which would close in the first half of 2021. The combined entity will operate under ImmunityBio moniker focused on oncology and infectious disease.
  • Price Action: NK stock gained 22.9% at $32 during premarket trading on the last check Friday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsFDAGeneralCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!